98%
921
2 minutes
20
This study aimed to develop models for predicting forkhead box protein A1 (FOXA1) gene mutations in prostate cancer using clinicoradiological and MRI radiomics data. Totally 367 prostate cancer patients (109 with FOXA1 mutations and 258 without) from three centers underwent multiparametric MRI. Patients from Center 1 (n = 236) were randomly divided into training and internal validation sets (7:3). Patients from Centers 2 and 3 (n = 131) were used for external validation. The index tumor lesion's volume of interest was delineated on MRI images to obtain 428 radiomics features for each patient. Radiomics features were selected by least absolute shrinkage and selection operator regression. Clinicoradiological features were compared between mutant and wild-type patients for feature selection. Those selected features were further chosen by binary logistic regression (LR) analysis, and used to develop prediction models for FOXA1 mutations with LR, support vector machine (SVM), and random forest (RF) classifiers. Models' performances were assessed by area under the receiver operating characteristic curve (AUC). No clinicoradiological feature was associated with FOXA1 mutations, while three radiomics features were selected to build models. AUCs of RF model in internal and external validation sets (0.82 and 0.81) were significantly greater than LR (0.74 and 0.71) and SVM (0.60 and 0.65) models (all p < 0.05), while AUC of LR model was greater than SVM model in internal validation set (p = 0.03). Radiomics method with RF classifier could effectively predict FOXA1 mutations in prostate cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215378 | PMC |
http://dx.doi.org/10.1038/s41598-025-04562-8 | DOI Listing |
J Pediatr Hematol Oncol
September 2025
Department of Pediatric, The University of Jordan.
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
View Article and Find Full Text PDFPLoS One
September 2025
Institute of Computational Science and Technology, Guangzhou University, Guangzhou, China.
MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology, yet their spatial dynamics within tumor microenvironments (TMEs) remain underexplored due to technical limitations in current spatial transcriptomics (ST) technologies. To address this gap, we present STmiR, a novel XGBoost-based framework for spatially resolved miRNA activity prediction. STmiR integrates bulk RNA-seq data (TCGA and CCLE) with spatial transcriptomics profiles to model nonlinear miRNA-mRNA interactions, achieving high predictive accuracy (Spearman's ρ > 0.
View Article and Find Full Text PDFClin Cancer Res
September 2025
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Human Kallikrein 2 (KLK2) is a prostate cancer tissue specific protein that is regulated by androgen receptor (AR) signaling. KLK2 was not previously recognized as a therapeutic target as it is secreted. It has now been demonstrated that KLK2 is expressed on the cell surface and targetable by various methodologies.
View Article and Find Full Text PDFInorg Chem
September 2025
Centre for Nanotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, India.
This study focuses on designing and developing a novel three-dimensional porphyrinic covalent organic framework (3D-Por-COF) to enhance anticancer sono-photodynamic therapy (SPDT). Leveraging the unique structural advantages of 3D COFs, this work addresses the limitations of traditional 2D-Por-COFs, particularly regarding reactive oxygen species (ROS) production and therapeutic efficacy. The newly developed 3D-Por-COF demonstrated significantly higher ROS generation under combined sonodynamic and photodynamic conditions, leading to an improved therapeutic effect against prostate cancer cells.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.